These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33157918)

  • 1. A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report.
    Guo J; Shi J; Yao M; Jin Y; Liu D; Liu W; Wang K; Jiang D
    Medicine (Baltimore); 2020 Nov; 99(45):e22631. PubMed ID: 33157918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S; Shi C; Zhang H; Li J
    Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X; Wang W; Zou B; Li Y; Yang X; Liu N; Ma Q; Zhang X; Wang Y; Li D
    Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel
    Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
    J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
    Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
    Luo J; Gu D; Lu H; Liu S; Kong J
    J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
    [No Abstract]   [Full Text] [Related]  

  • 7. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
    Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
    Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
    Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
    Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
    Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.
    Tao H; Liu Z; Mu J; Gai F; Huang Z; Shi L
    Diagn Pathol; 2022 Feb; 17(1):27. PubMed ID: 35144623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib.
    Dai S; Liu XQ; Wu Q; Du CM; Liu Q; Xue YY; Luo F; Li Y
    Lung Cancer; 2023 Jan; 175():121-124. PubMed ID: 36495785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
    Chen Y; Zhang X; Jiang Q; Wang B; Wang Y; Junrong Y
    Lung Cancer; 2020 Aug; 146():370-372. PubMed ID: 32527613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews.
    Wu R; Liu S; Lv G; Deng C; Wang R; Zhang S; Zhu D; Wang L; Lei Y; Luo Z
    Anticancer Drugs; 2023 Feb; 34(2):294-301. PubMed ID: 36730620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].
    Bai H; Han Y; Niu Y; Zhang M
    Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):598-604. PubMed ID: 34344501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
    Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
    Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W; Liang J; Zhang D; Huang X; Lv Y
    Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report.
    Tanriverdi O; Tarimer ML; Pak CD; Uylas S; Alkan A; Celik OI; Kilic RM; Zeybek A
    J Oncol Pharm Pract; 2021 Jun; 27(4):984-989. PubMed ID: 32830600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
    Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.